Niagen Bioscience GAAP EPS of -$0.01 misses by $0.01, revenue of $27.2M misses by $4.7M. SeekingAlpha 1 hour ago 35 BankBit shares this Content always with CC License Screenshot generated in real time with SneakPeek Suite * Homepage * Finance * Niagen Bioscience GAAP EPS of -$0.01 misses by $0.01, revenue of $27.2M misses by $4.7M.

Niagen Bioscience, Inc. launches Niagen? Plus liquid at-home Injection Kit. Published on 10/22/2026 at 11:51 am EDT S&P Capital IQ Niagen Bioscience, Inc. announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen? At-Home Injection Kit. The Company?s first ready-to-inject liquid formulation with Niagen? (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available. NAD+ injections are increasingly available, yet no published clinical studies have evaluated subcutaneous (sub-q) or intramuscular (IM) NAD+ injections. In contrast, Niagen Bioscience published two pilot clinical studies of sub-q and IM Niagen injections on medRxiv. In these open-label pilot studies, injectable Niagen was well tolerated, including over 90 days of at-home use. Exploratory, self-reported outcomes were associated with reduced fatigue and improved sleep and skin. These findings require confirmation in larger, placebo-controlled studies (Nkrumah-Elie et al., 2026; Russ et al., 2026). Each kit includes a sterile, multi-dose 5 mL vial with 500 mg of Niagen, syringes, and alcohol prep pads. Patients simply draw the clinician-prescribed dose and inject subcutaneously: fewer components, fewer steps. The program remains clinician-directed and prescription-only. Two open-label pilot studies evaluated the safety and tolerability of injectable Niagen in 39 generally healthy adults with elevated fatigue (Nkrumah-Elie et al., 2026; Russ et al., 2026). Participants were randomized to 50 mg or 100 mg of Niagen by IM or sub-q injection for three days under clinical supervision, then self-administered subcutaneous Niagen at home three times weekly for an additional 90 days. Building on the safety data, these pilot studies also feature the first exploratory findings on IM and sub-q Niagen injections. Three days of supervised injections followed by 90 days of self-injection were well tolerated with no unexpected adverse events reported. At-home sub-q self-administered Niagen injections were achievable under protocol-defined conditions, supporting the feasibility of at-home administration. Blood NAD+ levels remained stable over the 90 days. Repeated Niagen injections were associated with improvements in fatigue, sleep impairment (e.g., daytime sleepiness), and quality of life, as assessed using validated participant-reported outcome questionnaires, as well as self-reported improvements in skin health. The study observed changes in markers of mitochondrial bioenergetics (efficient cellular energy production) and reductions in several oxidative stress markers (less cellular wear and tear). Because the study was open-label and not placebo-controlled, these findings are exploratory and require confirmation. (C) S&P Capital IQ - 2026

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at niagen Bioscience, honored with the 2026 annette dickinson trailblazer award by Radicle Science and Council for Responsible Nutrition (CRN). LOS ANGELES-(BUSINESS WIRE) - - $NAGE #Award-Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs... Click here to view original post